Aroda, Vanita |
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor |
|
|
| Recruiting | 3 | 1250 | Canada, US, RoW | Retatrutide, LY3437943, Semaglutide | Eli Lilly and Company | Diabetes Mellitus, Type 2 | 12/26 | 03/27 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes |
|
|
| Recruiting | N/A | 320 | Europe, US | Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham) | Fractyl Health Inc. | Type 2 Diabetes | 06/24 | 01/26 | | |
VITAL-CGM, NCT05935514: Improving Glycemic Control Using a Virtual Weight Control Program and Continuous Glucose Monitoring |
|
|
| Recruiting | N/A | 396 | US | WW Intervention, Usual Care | Pennington Biomedical Research Center, Weight Watchers International | Diabetes Mellitus, Type 2 Diabetes, Obesity | 12/24 | 12/24 | | |
Park, Jean |
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor |
|
|
| Recruiting | 3 | 1250 | Canada, US, RoW | Retatrutide, LY3437943, Semaglutide | Eli Lilly and Company | Diabetes Mellitus, Type 2 | 12/26 | 03/27 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Overweight and Obesity | 02/29 | 02/29 | | |
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy |
|
|
| Completed | 3 | 692 | Europe, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Type 1 Diabetes, Diabetes | 05/24 | 05/24 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 09/25 | 09/27 | | |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
NCT05343065: A Continuous Glucose Monitor Based Insulin Bolus Calculator (CGM-IBC) Study B |
|
|
| Completed | N/A | 27 | US | BlueStar 10 | Welldoc | Diabetes Mellitus | 12/22 | 12/22 | | |
| Recruiting | N/A | 240 | US | EndoBarrier Liner, EndoBarrier Sleeve, Duodenal-jejunal Bypass Liner (DJBL), Sham | GI Dynamics, Biostatistical Consulting, Inc. | Diabetes type2, Obesity | 04/24 | 04/25 | | |
NCT05238142: In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes |
|
|
| Recruiting | N/A | 575 | US | MiniMed™ 780G Insulin Pump system | Medtronic Diabetes | Type 2 Diabetes Treated With Insulin | 10/24 | 02/25 | | |